作者:Maizatul Ibrahim、Mohd Mohd Yusof、Nakisah Amin
DOI:10.3390/molecules19045191
日期:——
Thiourea derivatives display a broad spectrum of applications in chemistry, various industries, medicines and various other fields. Recently, different thiourea derivatives have been synthesized and explored for their anti-microbial properties. In this study, four carbonyl thiourea derivatives were synthesized and characterized, and then further tested for their anti-amoebic properties on two potential pathogenic species of Acanthamoeba, namely A. castellanii (CCAP 1501/2A) and A. polyphaga (CCAP 1501/3A). The results indicate that these newly-synthesized thiourea derivatives are active against both Acanthamoeba species. The IC50 values obtained were in the range of 2.39–8.77 µg·mL‑1 (9.47–30.46 µM) for A. castellanii and 3.74–9.30 µg·mL‑1 (14.84–31.91 µM) for A. polyphaga. Observations on the amoeba morphology indicated that the compounds caused the reduction of the amoeba size, shortening of their acanthopodia structures, and gave no distinct vacuolar and nuclear structures in the amoeba cells. Meanwhile, fluorescence microscopic observation using acridine orange and propidium iodide (AOPI) staining revealed that the synthesized compounds induced compromised-membrane in the amoeba cells. The results of this study proved that these new carbonyl thiourea derivatives, especially compounds M1 and M2 provide potent cytotoxic properties toward pathogenic Acanthamoeba to suggest that they can be developed as new anti-amoebic agents for the treatment of Acanthamoeba keratitis.
硫脲衍生物在化学、各种工业、医药和其他领域有着广泛的应用。最近,人们合成了不同的硫脲衍生物,并探索了它们的抗微生物特性。 本研究合成了四种羰基硫脲衍生物并对其进行了表征,然后进一步测试了它们对两种潜在致病性棘阿米巴的抗阿米巴特性,这两种棘阿米巴分别是卡斯特拉氏棘阿米巴(CCAP 1501/2A)和多棘阿米巴(CCAP 1501/3A)。结果表明,这些新合成的硫脲衍生物对这两种棘阿米巴都有活性。卡斯特拉氏阿米巴虫的 IC50 值范围为 2.39-8.77 µg-mL-1 (9.47-30.46 µM),多棘阿米巴虫的 IC50 值范围为 3.74-9.30 µg-mL-1 (14.84-31.91 µM)。对变形虫形态的观察表明,这些化合物导致变形虫体积缩小,棘足结构缩短,并且在变形虫细胞中没有明显的空泡和核结构。同时,利用吖啶橙和碘化丙啶(AOPI)染色进行荧光显微镜观察发现,合成的化合物会导致变形虫细胞膜受损。研究结果表明,这些新的羰基硫脲衍生物,尤其是化合物 M1 和 M2 对致病性阿米巴具有很强的细胞毒性,建议将其开发为治疗阿米巴角膜炎的新型抗阿米巴药剂。